Trials / Completed
CompletedNCT07366372
Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients
The Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.
Detailed description
The central venous catheter (CVC) is highly frequent in the intensive care unit (ICU), with an average use rate between 32% and 80% among adult ICU patients. The utilization of CVC in ICUs has escalated over the past decade, accompanied by a corresponding increase in problems related to their usage. Taurolidine is a nontoxic substance having antibacterial impacts counter to mutually gram-positive and -negative bacteria, additionally to fungus. It decreases biofilm development and doesn't develop resistance to antibiotics, since it serves as an antiseptic rather than an antibiotic Consequently, it may function as a locking mechanism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Saline | Central venous catheters (CVCs) were locked with 2ml saline as a control group. |
| DRUG | Tigecycline and heparin | Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml. |
| DRUG | Taurolidine-citrate-heparin | Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin). |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
- First posted
- 2026-01-26
- Last updated
- 2026-01-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07366372. Inclusion in this directory is not an endorsement.